Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 74, Issue 4, 2015, Pages 730-737

  Moinzadeh, Pia ^a   Aberer, Elisabeth ^b   Ahmadi Simab, Keihan ^c   Blank, Norbert ^d   Distler, Joerg H W ^e   Fierlbeck, Gerhard ^f   Genth, Ekkehard ^g   Guenther, Claudia ^h   Hein, Ruediger ⁱ   Henes, Joerg ^f   Herich, Lena ^a   Herrgott, Ilka ^j   Koetter, Ina ^k   Kreuter, Alexander ^l   Krieg, Thomas ^a   Kuhr, Kathrin ^a   Lorenz, Hanns Martin ^d   Meier, Florian ^m   Melchers, Inga ⁿ   Mensing, Hartwig ^o   Mueller Ladner, Ulf ^m   Pfeiffer, Christiane ^p   Riemekasten, Gabriela ^q   Sárdy, Miklós ^r   Schmalzing, Marc ^f   Sunderkoetter, Cord ^j   Susok, Laura ^s   Tarner, Ingo H ^m   Vaith, Peter ⁿ   Worm, Margitta ^q   Wozel, Gottfried ^h   Zeidler, Gabriele ^t   Hunzelmann, Nicolas ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Asklepios Clinic Altona   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g Department of Rheumatology Clinic of Rheumatology of Aachen   (Germany)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k ROBERT BOSCH HOSPITAL   (Germany)

^l Department of Dermatology   (Germany)

^m KERCKHOFF HEART CENTER   (Germany)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o Clinic for Dermatology Hamburg Alstertal   (Germany)

^p UNIVERSITY HOSPITAL ULM   (Germany)

^q HUMBOLDT UNIVERSITY   (Germany)

^r LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^s RUHR UNIVERSITY BOCHUM   (Germany)

^t Johanniter Hospital   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; KU ANTIBODY; LA ANTIBODY; PMSCL ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE COURSE; ESOPHAGUS DISEASE; FEMALE; GERMANY; HEART DISEASE; HUMAN; KIDNEY DISEASE; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS OVERLAP SYNDROME; CARDIOMYOPATHIES; COMPLICATION; DIFFUSE SCLERODERMA; FACTUAL DATABASE; GASTROINTESTINAL DISEASES; HYPERTENSION, PULMONARY; IMMUNOLOGY; LIMITED SCLERODERMA; PATHOPHYSIOLOGY; PULMONARY FIBROSIS; SYNDROME; SYSTEMIC SCLEROSIS;

ADULT; AUTOANTIBODIES; CARDIOMYOPATHIES; CONNECTIVE TISSUE DISEASES; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SYNDROME;

EID: 84925601866     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204487     Document Type: Article

References (37)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
3. Galluccio F, Walker UA, Nihtyanova S, et al. Registries in systemic sclerosis: A worldwide experience. Rheumatology (Oxford) 2011; 50: 60-8.
4. Balbir-Gurman A, Braun-Moscovici Y. Scleroderma overlap syndrome. Isr Med Assoc J 2011; 13: 14-20.
5. Elhai M, Avouac J, Kahan A, et al. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013.
6. Cappelli S, Bellando Randone S, Martinovic D, et al. "To be or not to be," ten years after: Evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41: 589-98.
7. Ziswiler HR, Urech R, Balmer J, et al. Clinical diagnosis compared to classification criteria in in a cohort of 54 patients with systemic sclerosis and associated disorders. Swiss Med Wkly 2007; 137: 586-90.
8. Fiori G, Pignone A, Cerinic MM. Overlap syndromes. Reumatizam 2002; 49: 12-15.
9. Jury EC, D'Cruz D, Morrow WJ. Autoantibodies and overlap syndromes in autoimmune rheumatic disease. J Clin Pathol 2001; 54: 340-7.
10. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 71: 1355-60.
11. Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol 1999; 455: 85-92.
12. Pakozdi A, Nihtyanova S, Moinzadeh P, et al. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 2011; 38: 2406-9.
13. Hashimoto A, Endo H, Kondo H, et al. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22: 272-9.
14. Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes. Autoimmun Rev 2013; 12: 363-73.
15. Jablonska S, Blaszyk M. Scleromyositis (scleroderma/polimyositis overlap) is an entity. J Eur Acad Dermatol Venereol 2004; 18: 265-6.
16. Szucs G, Szekanecz Z, Zilahi E, et al. Systemic sclerosis-rheumatoid arthritis overlap syndrome: A unique combination of features suggests a distinct genetic, serological and clinical entity. Rheumatology (Oxford) 2007; 46: 989-93.
17. Ueda-Hayakawa I, Hasegawa M, Kumada S, et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 2010; 49: 2135-9.
18. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5: 80-93.
19. Maddison PJ. Overlap syndromes and mixed connective tissue disease. Curr Opin Rheumatol 1991; 3: 995-1000.
20. Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: Autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15: 102-9.
21. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
22. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6: 112-16.
23. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. Curr Opin Rheumatol 2004; 16: 723-32.
24. Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992; 35: 1211-17.
25. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: Frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185-92.
26. Hunzelmann N, Moinzadeh P, Genth E, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009; 11: R30.
27. Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-Associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: Correlation with characteristic clinical features. Arthritis Res Ther 2011; 13: R172.
28. Alarcon GS. Unclassified or undifferentiated connective tissue disease. Best Pract Res Clin Rheumatol 2000; 14: 125-37.
29. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-51.
30. Caramaschi P, Biasi D, Volpe A, et al. Coexistence of systemic sclerosis with other autoimmune diseases. Rheumatol Int 2007; 27: 407-10.
31. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008; 31: 156-9.
32. Koschik RW 2nd, Fertig N, Lucas MR, et al. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 2012; 30: S12-16.
33. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine 2005; 84: 231-49.
34. Burdt MAHR, Deutscher SL, Wang GS, et al. Long-Term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42: 899-909.
35. Schmeiser T, Pons-Kuhnemann J, Ozden F, et al. Arthritis in patients with systemic sclerosis. Eur J Intern Med 2012; 23: E25-9.
36. Hasegawa M, Hatta Y, Matsushita T, et al. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Mod Rheumatol 2012.
37. Skare TL, Fonseca AE, Luciano AC, et al. Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil. Anais brasileiros de dermatologia 2011; 86: 1075-81.